Choosing the Best Induction Therapy for Fit Patients With Myeloma | Jonathan Kaufman, MD

Choosing the Best Induction Therapy for Fit Patients With Myeloma | Jonathan Kaufman, MD

Can Patient Questionnaires Reduce the Need for Eye Exams with Belantamab?| Rakesh Popat, PhD

Can Patient Questionnaires Reduce the Need for Eye Exams with Belantamab?| Rakesh Popat, PhD

Teclistamab & CMV: Risks and Clinical Outcomes Explained | Samer Al Hadidi, MD

Teclistamab & CMV: Risks and Clinical Outcomes Explained | Samer Al Hadidi, MD

Can Sonrotoclax Improve Outcomes in t(11;14) Relapsed Myeloma? | Rakesh Popat, PhD

Can Sonrotoclax Improve Outcomes in t(11;14) Relapsed Myeloma? | Rakesh Popat, PhD

Insights from a community oncologist on myeloma bispecific antibodies | Ira Zackon, MD

Insights from a community oncologist on myeloma bispecific antibodies | Ira Zackon, MD

Preventing Myeloma Relapse Using a Response Adaptive Dosing Approach | Erin Meermeier, PhD

Preventing Myeloma Relapse Using a Response Adaptive Dosing Approach | Erin Meermeier, PhD

Belamaf + VRd for Newly Diagnosed Transplant-Ineligible Myeloma Patients | Saad Usmani, MD

Belamaf + VRd for Newly Diagnosed Transplant-Ineligible Myeloma Patients | Saad Usmani, MD

Monoclonal Gammopathy of Renal Significance: Hematologic Perspective | Heather Landau, MD

Monoclonal Gammopathy of Renal Significance: Hematologic Perspective | Heather Landau, MD

First U.S. CAR-T Trial for AL Amyloidosis Shows Promise | Heather Landau, MD

First U.S. CAR-T Trial for AL Amyloidosis Shows Promise | Heather Landau, MD

Real-Time Symptom Tracking for Myeloma Patients | James Berenson, MD

Real-Time Symptom Tracking for Myeloma Patients | James Berenson, MD

Long-Term Success with Talquetamab Combo Therapy | Hang Quach, MD

Long-Term Success with Talquetamab Combo Therapy | Hang Quach, MD

Dual Antibody Combo (Tec + Tal) Shows Hope for Hard-to-Treat Myeloma | Saad Usmani, MD

Dual Antibody Combo (Tec + Tal) Shows Hope for Hard-to-Treat Myeloma | Saad Usmani, MD